BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9209389)

  • 21. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma.
    Takita J; Hayashi Y; Kohno T; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
    Cancer Res; 1997 Mar; 57(5):907-12. PubMed ID: 9041193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Codeletion of p15 and p16 in primary malignant mesothelioma.
    Xio S; Li D; Vijg J; Sugarbaker DJ; Corson JM; Fletcher JA
    Oncogene; 1995 Aug; 11(3):511-5. PubMed ID: 7630635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL).
    Hatta Y; Koeffler HP
    Leukemia; 2002 Jun; 16(6):1069-85. PubMed ID: 12040438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
    Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
    Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
    Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia.
    Hatta Y; Hirama T; Miller CW; Yamada Y; Tomonaga M; Koeffler HP
    Blood; 1995 May; 85(10):2699-704. PubMed ID: 7742529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
    Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood.
    Ohnishi H; Hanada R; Horibe K; Hongo T; Kawamura M; Naritaka S; Bessho F; Yanagisawa M; Nobori T; Yamamori S; Hayashi Y
    Leukemia; 1996 Jul; 10(7):1104-10. PubMed ID: 8683987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene.
    Wiest JS; Franklin WA; Otstot JT; Forbey K; Varella-Garcia M; Rao K; Drabkin H; Gemmill R; Ahrent S; Sidransky D; Saccomanno G; Fountain JW; Anderson MW
    Cancer Res; 1997 Jan; 57(1):1-6. PubMed ID: 8988029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster.
    Aguiar RC; Sill H; Goldman JM; Cross NC
    Leukemia; 1997 Feb; 11(2):233-8. PubMed ID: 9009086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia.
    Batova A; Diccianni MB; Yu JC; Nobori T; Link MP; Pullen J; Yu AL
    Cancer Res; 1997 Mar; 57(5):832-6. PubMed ID: 9041181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.
    Packenham JP; Taylor JA; Anna CH; White CM; Devereux TR
    Mol Carcinog; 1995 Nov; 14(3):147-51. PubMed ID: 7576106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
    Brenner AJ; Aldaz CM
    Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma.
    Koduru PR; Zariwala M; Soni M; Gong JZ; Xiong Y; Broome JD
    Blood; 1995 Oct; 86(8):2900-5. PubMed ID: 7579381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level.
    Jamal R; Thomas NS; Gale RE; Linch DC
    Leukemia; 1996 Apr; 10(4):629-36. PubMed ID: 8618439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
    Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
    Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies.
    Dreyling MH; Bohlander SK; Le Beau MM; Olopade OI
    Blood; 1995 Sep; 86(5):1931-8. PubMed ID: 7544647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors.
    Ichikawa Y; Yoshida S; Koyama Y; Hirai M; Ishikawa T; Nishida M; Tsunoda H; Kubo T; Miwa M; Uchida K
    Int J Cancer; 1996 Dec; 69(6):466-70. PubMed ID: 8980248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas.
    Saxena A; Robertson JT; Ali IU
    Oncogene; 1996 Aug; 13(3):661-4. PubMed ID: 8760309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.